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Salmonella enterica serovars Typhi and Paratyphi A isolates from human patients in France
displaying different levels of resistance to quinolones or fluoroquinolones were studied for
resistance mechanisms to these antimicrobial agents. All resistant isolates carried either
single or multiple target gene mutations (i.e., in gyrA, gyrB, or parC) correlating with
the resistance levels observed. Active efflux, through upregulation of multipartite efflux
systems, has also been previously reported as contributing mechanism for other serovars.
Therefore, we investigated also the occurrence of non-target gene mutations in regulatory
regions affecting efflux pump expression. However, no mutation was detected in these
regions in both Typhi and Paratyphi isolates of this study. Besides, no overexpression of
the major efflux systems was observed for these isolates. Nevertheless, a large deletion
of 2334 bp was identified in the acrS-acrE region of all S. Typhi strains but which did
not affect the resistance phenotype. As being specific to S. Typhi, this deletion could
be used for specific molecular detection purposes. In conclusion, the different levels of
quinolone or FQ resistance in both S. Typhi and S. Paratyphi A seem to rely only on target
modifications.
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INTRODUCTION
Enteric fever caused by the human-adapted pathogens Salmonella
enterica serovars Typhi (S. Typhi) and Paratyphi A (S. Paratyphi
A), B, and C, remains a major health problem (Crump and Mintz,
2010). A global epidemiologic study estimated that during the
year 2000 typhoid fever caused 21.7 million illnesses and 21,7000
deaths and paratyphoid fever caused 5.4 million illnesses (Crump
et al., 2004). During the past decade S. Paratyphi A was responsi-
ble for a growing proportion of enteric fever in Asia (Ochiai et al.,
2005; Crump and Mintz, 2010). Enteric fever being associated
with poor sanitation and unsafe food and water, it particularly
affects children and adolescents in developing countries of Asia,
Africa and Latin America (Crump et al., 2004; Bhan et al., 2005;
Crump and Mintz, 2010). In developed countries, patients are
most often ill-returned travellers or migrant workers (Bhan et al.,
2005; Connor and Schwartz, 2005; Hassing et al., 2013).
To treat these infections, fluoroquinolones (FQ) and third-
generation cephalosporins have been considered as first-line
drugs, owing to the resistance to ampicillin, chloramphenicol,
and trimethoprim/sulfamethoxazole that appeared during the
1980s (Hassing et al., 2011, 2013). Multidrug resistance (MDR)
in S. Typhi is encoded mainly by resistance genes carried by
large conjugative plasmids and has been reported worldwide
(Le et al., 2007). As a consequence of a widespread FQ usage,
S. Typhi and S. Paratyphi A isolates resistant to nalidixic acid
(NALR, minimum inhibitory concentration [MIC] > 16 mg/L)
and with decreased susceptibility to ciprofloxacin (CIPDS, MIC
0.125–1.0 mg/L) have also emerged. Such NALR-CIPDS S. Typhi
and S. Paratyphi A have been isolated in endemic areas and also
in developed countries (Roumagnac et al., 2006; Le et al., 2007;
Gaborieau et al., 2010; Accou-Demartin et al., 2011; Hassing et al.,
2011, 2013).
Resistance to quinolones in Salmonella spp. is mostly
attributed to point mutations in the quinolone resistance-
determining regions (QRDRs) of the target genes gyrA, gyrB,
parC, and parE (Cloeckaert and Chaslus-Dancla, 2001; Piddock,
2002; Velge et al., 2005; Giraud et al., 2006). For the gyrA gene,
coding the A subunit of DNA gyrase, a single mutation result-
ing in an amino acid substitution at the position 83 (Serine to
Phenylalanine or to Tyrosine) or at the position 87 (Aspartic acid
to Asparagine or Glycine) has been the most frequently described
in NALR-CIPDS S. Typhi and S. Paratyphi A isolates (Bhan et al.,
2005; Renuka et al., 2005; Le et al., 2007; Gaborieau et al., 2010;
Hassing et al., 2011). A second mutation leading to the amino acid
change at the position 80 (Serine to Isoleucine or to Arginine) of
the ParC subunit of topoisomerase IV was described to increase
the CIP MIC (≥ 0.5 mg/L) in S. Typhi and S. Paratyphi A human
isolates from India (Gaind et al., 2006). Whereas three mutations,
i.e., a double mutation in gyrA at both codons 83 and 87 and
one mutation in parC, were shown to confer CIP resistance (MIC
>1 mg/L) in S. Typhi and S. Paratyphi A human isolates from
India or from Taiwan (Gaind et al., 2006; Lee et al., 2013).
Moreover, the varying levels of CIP resistance observed in
S. Typhi and S. Paratyphi A isolates with only a single gyrA
mutation suggest that other mechanisms could be involved
in quinolone resistance in this serovar (Renuka et al., 2005).
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Resistance to FQ in S. Typhimurium has also been attributed
to active efflux mechanism, due to overproduction of the
AcrAB-TolC efflux system (Giraud et al., 2000, 2006; Cloeckaert
and Chaslus-Dancla, 2001; Piddock, 2006). We have previ-
ously reported the contribution of the AcrAB-TolC efflux sys-
tem in resistance to FQ in several MDR epidemic clones of
S. Typhimurium, such as S. Typhimurium of phage types DT204
or DT104 (Baucheron et al., 2002, 2004a,b). Among the chro-
mosomal loci affecting AcrAB-TolC expression, the ramRA locus
appears to be the most important in Salmonella spp. (Abouzeed
et al., 2008; Kehrenberg et al., 2009). ramR encodes a repres-
sor protein (RamR) belonging to the TetR family of repressor
proteins, and has been shown to be the local repressor protein
of ramA transcription (Abouzeed et al., 2008; Baucheron et al.,
2012); while ramA encodes a transcriptional activator protein
(RamA) belonging to the AraC/XylS family of regulatory proteins
(Nikaido et al., 2008; Bailey et al., 2010). The latter is involved in
upregulating expression of the AcrAB-TolC system (Nikaido et al.,
2008; Bailey et al., 2010). Several mutations in ramR or its binding
site upstream of ramA, affecting expression of this efflux system,
have been detected in clinical isolates of serovar Typhimurium or
Kentucky and of minor serovars Hadar, Infantis, Livingstone, or
Schwarzengrund (Abouzeed et al., 2008; Kehrenberg et al., 2009;
Hentschke et al., 2010; Akiyama and Khan, 2012; Baucheron et al.,
2013).
In the present study, we have characterized mechanisms
involved in resistance to quinolones or fluroquinolones in 21
S. Typhi and S. Paratyphi A strains displaying different levels of
resistance to these drugs and isolated from patients in France
during the period 1997–2008. For a subset of strains, with
suspected increased efflux activity, we investigated the occurrence
of mutations in the global ram, sox and mar regulatory loci of
AcrAB-TolC, and in the local acrR and acrS repressor genes of
the AcrAB and AcrEF pumps, respectively (Abouzeed et al., 2008;
Kehrenberg et al., 2009).
MATERIALS AND METHODS
BACTERIAL STRAINS
The twenty one strains including 16 S. Typhi and 5 S. Paratyphi
A selected for this study were collected by the French National
Reference Center for Salmonella, Institut Pasteur, Paris, France.
They were isolated in France from travellers or migrants between
1997 and 2008 (Table 1). The selection was made to obtain
diversity in terms of geographic origin, year of isolation, genetic
lineages (haplotype for S. Typhi; Roumagnac et al., 2006), and
phenotype of resistance to quinolones (Table 1).
Table 1 | Salmonella enterica serovars Typhi and Paratyphi A strains analyzed in this study.
Strain Country Year of Haplo Antimicrobial MIC (mg/L) Substitution(s) in the QRDR of: AcrA production ratio*
isolation type resistance pattern
NAL CIP GyrA GyrB ParC ParE
SALMONELLA TYPHI
06–423 India 2006 ND Pansusceptible 4 0.015 WT WT WT WT 1
06–426 India 2006 ND CIPDS 16 0.125 WT S464Y WT WT 1
02–1180 India 2002 H45 NALCIPDS 64 0.125 D87G WT WT WT 1
05–3275 Morocco 2005 H6 NALCIPDS 64 0.125 D87N WT WT WT 1
4(02)MB Vietnam 1997 H58 ASCSulTmpTeNAL 128 0.03 S83Y WT WT WT 0.5
222(97)MN Vietnam 1996 ND ASCSulTmpTeNALCIPDS 128 0.125 S83F WT WT WT 0.5
43(97)MN Vietnam 1996 H63 ASCSulTmpTeNALCIPDS 128 0.125 S83F WT WT WT 0.5
98–3139 Mexico 1998 H50 NALCIPDS 128 0.125 S83F WT WT WT 0.5
02–7744 India 2002 H52 NALCIPDS 128 0.125 S83F WT WT WT 0.5
226(97)MN Vietnam 1996 H61 ASCSulTmpTeNALCIPDS 128 0.25 S83F WT WT WT 0.5
97–2307 India 1997 H63 NALCIPDS 256 0.125 S83F WT WT WT 0.5
318(98)MB Vietnam 1998 H58 ASCSulTmpTeNALCIPDS 512 0.25 S83Y WT WT WT 1
39(98)MN Vietnam 1998 H58 ASCSulTmpTeNALCIPDS 512 0.25 S83F WT WT WT 1
4(02)MN Vietnam 2000 H58 ASCSulTmpTeNALCIPDS 1024 0.25 S83F WT WT D420N 1
5(04)MN Vietnam 2004 ND NALCIPDS 1024 0.25 S83F WT WT D420N 1
04–2176 India 2004 H58 SSpSulTmpTeNALCIP 1024 8 S83F; D87N WT S80I WT 1
SALMONELLA PARATYPHI A
08–8903 Senegal 2008 Pansusceptible 8 0.030 WT WT WT WT 2
07–6329 Burkina Faso 2007 CIPDS 16 0.25 WT S464F WT WT 2
05–208 India 2005 NALCIPDS 256 0.50 S83F WT WT WT 2
08–4271 Guinea Bissau 2008 NACIPDS 1024 1 S83F WT WT WT 2
08–2580 India 2008 NALCIPDS 1024 1 S83F WT WT WT 3
*AcrA expression was measured by dot blotting with an anti-AcrA polyclonal antibody.
ND, not determined.
WT, wild type.
A, amoxicillin; S, streptomycin; Sp, spectinomycin; C, chloramphenicol; Sul, sulfamethoxazole; Tmp, trimethoprim; Te, tetracycline; NAL, nalidixic acid; CIP,
ciprofloxacin; CIPDS , decreased susceptibility to ciprofloxacin.
D, aspartic acid; F, phenylalanine; G, glycine; I, isoleucine; N, asparagine; S, serine; Y, tyrosine.
Frontiers in Microbiology | Antimicrobials, Resistance and Chemotherapy January 2014 | Volume 5 | Article 12 | 2
Baucheron et al. Quinolone resistance mechanisms in Salmonella
ANTIMICROBIAL SUSCEPTIBILITY TESTING
Antimicrobial susceptibility was investigated by the standard
disk diffusion method according to the recommendations of the
Antibiogram Committee of the French Society for Microbiology
(CA-SFM) (www.sfm-microbiologie.org/). The MICs of NAL
and CIP were determined by the standard agar doubling dilu-
tion method as described previously (Baucheron et al., 2002).
The NALR isolates were defined as having a MIC > 16 mg/L.
The CIPR isolates were defined as having a MIC > 1 mg/L and
CIPDS isolates as having a MIC comprised between 0.125 and
1.0 mg/L (Accou-Demartin et al., 2011; Hassing et al., 2013).
MICs of these antibiotics were also determined in the pres-
ence of the efflux pump inhibitor Phe-Arg-β-naphthylamide
(PAβN, Sigma) at the following concentrations: 10, 20, 30, 40, 50,
and 60 mg/L.
ASSESSMENT OF TARGET-AFFECTING MECHANISMS
Mutations in the QRDRs of gyrA, gyrB, parC, and parE genes were
detected as described previously (Le et al., 2007; Song et al., 2010;
Accou-Demartin et al., 2011).
The search of plasmid-mediated quinolone resistances genes,
qnrA, qnrB, qnrS, qnrD, aac(6’)-Ib-cr, and qepA was performed as
described previously (Accou-Demartin et al., 2011).
ASSESSMENT OF EFFLUX MECHANISMS
Efflux pump production was assessed by dot blot using an anti-
AcrA polyclonal antibody as described previously (Abouzeed
et al., 2008). Occurrence of mutations affecting acrAB, acrEF, and
tolC expression was determined by PCR and sequencing the regu-
latory regions ramR-ramA, acrR-acrA, marC-marO-marR-marA,
soxS-soxR, and acrS-acrE using primers listed in (Table 2).
Table 2 | Primers used for PCRs.
Primer used Primer Nucleotide position Oligonucleotide sequence(s) (5’–3’) Size (bp) Annealing Reference
and target relative to the LT2 strain temp (◦C)
region genome sequence*
DETECTION OF MUTATIONS
ramR-ramA ram5 638085 TCGGTAAAAGGCAGTTCCAG 958 60 Baucheron et al., 2013
ramA6 639042 GTCGATAACCTGAGCGGAAA
acrR-acrA acrR1 533463 CAGTGGTTCCGTTTTTAGTG 992 58 Olliver et al., 2005
acrR2 534454 ACAGAATAGCGACACAGAAA
marC-marO-
marR-marA
marR1 1597459 CAGTGTTGCGTCTGGACATC 787 60 Baucheron et al., 2013
marR2 1598245 GCTAACGGGAGCAGTACGAC
soxS-soxR sox1 4503970 CTACAGGCGGTGACGGTAAT 915 60 Baucheron et al., 2013
sox2 4504884 CGGCGCTTTAGTTTTAGGTG
acrS-acrE acrS3 3559106 AAAACGAACGGGAACTGATG 2874 ∗∗∗ 58 This study
acrS4 3561978 ACAAACATACCGGGAAGCAG
qRT-PCR
gmk gmk-f 3933294 TTGGCAGGGAGGCGTTT 62 60 Baucheron et al., 2012
gmk-r 3933355 GCGCGAAGTGCCGTAGTAAT
gyrB gyrB-f 4040275 TCTCCTCACAGACCAAAGATAAGCT 81 60 Baucheron et al., 2012
gyrB-r 4040195 CGCTCAGCAGTTCGTTCATC
rrs rrs-f NA∗∗ CCAGCAGCCGCGGTAAT 57 60 Baucheron et al., 2012
rrs-r NA∗∗ TTTACGCCCAGTAATTCCGATT
ramA ramA-f 639180 GCGTGAACGGAAGCTAAAAC 167 60 Baucheron et al., 2012
ramA-r 639346 GGCCATGCTTTTCTTTACGA
ramR ramR-f 638623 TAACGCAGGTGTTGCAGAAG 192 64 Baucheron et al., 2012
ramR-r 638432 TGGTTCAGACCCCAACTGAT
acrA acrA-f 533120 GAAACCGCACGTATCAACCT 220 60 Baucheron et al., 2012
acrA-r 532901 CCTGTTTCAGCGAACCATTT
acrB acrB-f 531348 TCGTGTTCCTGGTGATGTACCT 68 66 Baucheron et al., 2012
acrB-r 531281 AACCGCAATAGTCGGAATCAA
acrF acrF-f 3563042 GCTCTGTCGTCCATCTCAAAGA 70 66 This study
acrF-r 3563111 CGCGCTACAACGTTATAGTTTTCA
tolC tolC-f 3349107 GCCCGTGCGCAATATGAT 67 60 Baucheron et al., 2012
tolC-r 3349173 CCGCGTTATCCAGGTTGTTG
*GenBank NC_003197.1.
**NA: Not Applicable due to the number of copies of this gene in Salmonella.
***2874 bp for S. Typhimurium or S. Paratyphi A and 539 bp for S. Typhi (see Figure 1).
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Transcription levels of efflux related genes acrA, acrB, acrF, tolC,
ramA, and ramR were done by quantitative reverse transcription-
PCR (qRT-PCR) as described previously (Baucheron et al., 2012;
Giraud et al., 2013). Primers used for qRT-PCR are listed in
(Table 2).
RESULTS AND DISCUSSION
RESISTANCE PHENOTYPES AND TARGET-AFFECTING MECHANISMS
The twenty one S. Typhi and S. Paratyphi A strains of this study
were isolated in France but acquired abroad, mainly in Asia
and Africa (Table 1). Among the S. Typhi strains, all but two
were NALR (MIC > 16 mg/L). One of the two strains was pan-
susceptible and the second was CIPDS but only categorized as
intermediate for NAL (NALI, MIC 16 mg/L). Of the 14 NALR
strains, one was CIPR, 12 were CIPDS and one was CIPS (MIC
0.03 mg/L). Eight NALR S. Typhi strains were also multidrug
resistant. The majority of the NALR S. Typhi strains belonged to
haplotype H58 which had emerged in Southern Asia during the
mid 1990s (Roumagnac et al., 2006; Le et al., 2007). Among the
S. Paratyphi A strains, all but two were NALR. One of the two
strains was pansusceptible and the second was NALI-CIPDS. The
three others were NALR- CIPDS.
As shown in Table 1, both NALI-CIPDS had a mutation result-
ing in an amino acid substitution at position 464 of GyrB: serine
to tyrosine for the S. Typhi isolate and serine to phenylalanine for
the S. Paratyphi A isolate. The most frequent mechanism of resis-
tance of NALR-CIPDS (n = 17) and NALR-CIPS (n = 1) strains,
whatever the serovar, was a substitution at position 83 (serine
to phenylalanine, n = 12, 66.6%) of GyrA. Other GyrA modifi-
cations were observed at position 83 (serine to tyrosine) in two
isolates or at position 87 (aspartic acid to glycine, aspartic acid
to asparagine) in one isolate for each. As described previously,
a single substitution in GyrA was associated with resistance to
nalidixic acid and decreased susceptibility to CIP (Bhan et al.,
2005; Le et al., 2007; Gaborieau et al., 2010; Hassing et al., 2011).
One exception was the S. Typhi strain 4 (02) MB, which was
NALR-CIPS (and not CIPDS) despite a mutation in gyrA resulting
in substitution serine to tyrosine at position 83.
Additional substitutions were found in ParE of 2 NALR-CIPDS
S. Typhi strains that led to amino acid substitution aspartic acid
to asparagine at position 420. In both cases, a 2-fold increase of
NAL MICs was observed.
In the CIPR S. Typhi isolate, three mutations leading to a dou-
ble substitution in GyrA at positions 83 (serine to phenylalanine)
and 87 (aspartic acid to asparagine) and one substitution at the
position 80 of ParC (serine to isoleucine), as observed in previous
studies (Renuka et al., 2005; Gaind et al., 2006; Lee et al., 2013).
The NALR and CIPDS S. Typhi and S. Paratyphi A strains har-
boring a single substitution in GyrA showed various values for
NAL (64–1024 mg/L) and CIP (0.03–0.5 mg/L) MICs which sug-
gested the presence of other mechanisms of resistance. Since the
plasmid-mediated quinolone resistance-conferring genes qnrA,
qnrB, qnrD or qnrS, qepA, and aac(6′)-Ib-cr were not detected,
we investigated the role of the AcrAB-TolC efflux system.
INVOLVEMENT OF EFFLUX
None of the S. Typhi strains showed significant AcrA overpro-
duction by dot blot, but nevertheless all S. Paratyphi A isolates
showed a 2 or 3-fold increased AcrA production relative to the
susceptible S. Typhi isolate (Table 1). Thus, overproduction of
AcrA seems not to be involved in CIPDS isolates compared with
the susceptible isolates of S. Typhi or S. Paratyphi A. In presence
of the efflux pump inhibitor PAβN (20 or 40 mg/L), the CIP
MICs similarly decreased (4 or 8-fold) in CIPDS and in suscep-
tible strains (Table 3 and data not shown), which is in accordance
with previous studies on S. Typhimurium and corresponds to
Table 3 | Study of efflux in a subset of Salmonella enterica serovars Typhi and Paratyphi A strains.
Strain Antimicrobial
resistance patterna
MIC (mg/L)b Substitution(s) in the QRDR of c: acrSE
sequencing
Transcription level of:
NAL CIP GyrA GyrB ParC ParE acrA acrF acrB tolC ramA ramR
SALMONELLA TYPHI
06–423 Pansusceptible 4 0.015 [0.004] WT WT WT WT Deletiond 1.0 1.0 1.0 1.0 1.0 1.0
02–1180 NALCIPDS 64 0.125 [0.015] D87G WT WT WT Deletiond 1.5 0.7 0.5 0.8 0.9 1.4
05–3275 NALCIPDS 64 0.125 [0.030] D87N WT WT WT Deletiond 0.5 1.4 0.2 0.5 0.3 0.7
97–2307 NALCIPDS 256 0.125 [0.030] S83F WT WT WT Deletiond 1.7 0.8 0.8 0.7 1.9 2.2
04–2176 SSpSulTmpTeNALCIP 1024 8 [2] S83F; WT S80I WT Deletiond 1.5 0.8 1.3 0.9 1.2 2.2
A87N
SALMONELLA PARATYPHI A
08–8903 Pansusceptible 8 0.030 [0.008] WT WT WT WT WT 1.0 1.0 1.0 1.0 1.0 1.0
07–6329 CIPDS 16 0.25 [0.060] WT S464F WT WT WT 1.6 1.4 1.0 1.0 1.0 1.2
05–208 NALCIPDS 256 0.50 [0.030] S83F WT WT WT WT 1.3 0.9 1.4 1.0 1.1 1.0
08–4271 NALCIPDS 1024 1 [0.25] S83F WT WT WT WT 1.2 1.1 0.7 1.4 1.3 1.3
08–2580 NALCIPDS 1024 1 [0.25] S83F WT WT WT WT 2.0 1.6 1.4 1.4 2.0 1.3
aS, streptomycin; Sp, spectinomycin; Sul, sulfamethoxazole; Tmp, trimethoprim; Te, tetracycline; NAL, nalidixic acid; CIP, ciprofloxacin; CIPDS , decreased suscepti-
bility to ciprofloxacin.
bValues in brackets are MICs in the presence of the efflux pump inhibitor PAβN at 40 mg/L.
cWT, wild type; D, aspartic acid; F, phenylalanine; G, glycine; I, isoleucine; N, asparagine; S, serine.
d 2334 bp deleted.
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FIGURE 1 | Deletion identified in the acrSE region relative to the
genome sequence of S. Typhi strain CT18 (GenBank NC_003198.1).
The sequence of the acrSE region of S. Typhi strain CT18 is compared
to those of S. Paratyphi A strain ATCC9150 (GenBank NC_006511.1) and
S. Typhi strain LT2 (GenBank NC_003197.1). Small black arrows indicate
primers positions used for PCR to amplify and sequence the acrSE
region. The 2334 bp chromosomal deletion was found in all S. Typhi
strains studied.
a decrease of resistance level observed for acrB or tolC deletion
mutants (Baucheron et al., 2002, 2004b).
Despite a lack of evidence of increased efflux in the resis-
tance phenotype, we measured by qRT-PCR the transcription
levels of efflux related genes acrA, acrF, acrB, tolC, ramA, and
ramR in CIPDS non-MDR strains and in the CIPR strain. No
differences were detected in the transcription levels of these
genes, between susceptible, CIPDS and CIPR strains, whatever the
serovar (Table 3). In addition, no mutations were detected in the
regulatory regions of the AcrAB-TolC efflux system. However,
during the screening of the regulatory regions, we identified a
single large deletion of 2334 bp in the acrS-acrE region of all
S. Typhi strains, including the susceptible one (Table 3). This
deletion encompassed the acrS gene, that encodes a transcrip-
tional repressor, and a large part of the acrE gene that encodes
the AcrE periplasmic lipoprotein, which is homologous to AcrA
(Olliver et al., 2005). This 2334 bp deletion was also observed
in the acrS-acrE region of sequenced genomes of MDR S. Typhi
CT18 strain (Parkhill et al., 2001) and pansusceptible TY2 strain
(Deng et al., 2003) (Figure 1). Previously, it has been shown that
acrS deletion in S. Typhimurium does not affect acrEF expres-
sion (Olliver et al., 2005). Similarly the natural acrSE deletion
detected in S. Typhi had no impact on the acrF transcription
level as observed in this study. To our knowledge, this is the first
description of such a natural acrS-acrE chromosomal deletion
and seems specific to S. Typhi since it was not detected in all
currently sequenced genomes of the other serovars (not shown).
CONCLUSIONS
The main mechanisms involved in quinolone or FQ resistance
in both S. Typhi and S. Paratyphi A are target modifications.
In contrast to what is seen in enteric pathogenic serovars, such
as Typhimurium or the emerging CIPR Kentucky ST198 clone
(Baucheron et al., 2013), increased efflux pump production-
mediated mechanisms seem to be totally absent in both S. Typhi
and S. Paratyphi A. The deletion identified in the acrSEF region,
although not involved in the resistance phenotype, may be helpful
for the specific detection of S. Typhi.
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